Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.52 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.47 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.47 |
| ▸ | YARS1 | P54577 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17834728 | 0.86 | CXCR1 (0.51) | SLC7A5CXCR1CXCR2THRB | |
| SCHEMBL16836845 | 0.86 | ALPI (0.56) | SLC7A5CXCR1CXCR2THRB | |
| SCHEMBL16727787 | 0.86 | ALPI (0.56) | SLC7A5CXCR1CXCR2THRB | |
| Hydrochloric Acid SCHEMBL17825443 | 0.85 | CXCR1 (0.50) | CXCR1CXCR2THRB | |
| Hydrochloric Acid SCHEMBL17825499 | 0.85 | CXCR1 (0.50) | CXCR1CXCR2THRB | |
| Tyrosine SCHEMBL17874441 | 0.81 | SLC7A5 (0.80) | SLC7A5TAAR1SLC6A2YARS1 | |
| Tyrosine SCHEMBL17874442 | 0.81 | SLC7A5 (0.80) | SLC7A5TAAR1SLC6A2YARS1 | |
| SCHEMBL30708085 | 0.80 | SLC7A5 (0.62) | SLC7A5TAAR1SLC6A2LNPEPERAP2 | |
| SCHEMBL2013830 | 0.80 | SLC7A5 (0.62) | SLC7A5TAAR1SLC6A2LNPEPERAP2 | |
| SCHEMBL2017291 | 0.80 | SLC7A5 (0.62) | SLC7A5TAAR1SLC6A2LNPEPERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1999052906-A1 | SUBSTITUTED OXAZOLYLE AND THIAZOLYL URACIL HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-10-21 | — | — | WO | claimed |
| EP-3925627-A1 | DRUG-CONJUGATES AND USES THEREOF | Concortis Biosystems, Corp (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3590541-B1 | DRUG-CONJUGATES AND USES THEREOF | CONCORTIS BIOSYSTEMS CORP (US) | 2021-08-11 | — | — | EP | disclosed |
| US-20210187119-A1 | Drug-Conjugates, Conjugation Methods, And Uses Thereof | VIVASOR, INC. | 2021-06-24 | — | — | US | disclosed |
| US-10967071-B2 | Drug-conjugates, conjugation methods, and uses thereof | CONCORTIS BIOSYSTEMS, CORP. (US) | 2021-04-06 | — | — | US | disclosed |
| EP-3520817-A1 | DRUG-CONJUGATES, CONJUGATION METHODS, AND USES THEREOF | Concortis Biosystems, Corp (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-2849790-B1 | DRUG-CONJUGATES, CONJUGATION METHODS, AND USES THEREOF | CONCORTIS BIOSYSTEMS CORP (US) | 2019-04-10 | — | — | EP | disclosed |
| US-9981046-B2 | Drug-conjugates, conjugation methods, and uses thereof | Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180085471-A1 | DRUG-CONJUGATES, CONJUGATION METHODS, AND USES THEREOF | SORRENTO THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180085471-A1 | DRUG-CONJUGATES, CONJUGATION METHODS, AND USES THEREOF | SORRENTO THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-9884127-B2 | Drug-conjugates, conjugation methods, and uses thereof | CONCORTIS BIOSYSTEMS, CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9801951-B2 | Drug-conjugates, conjugation methods, and uses thereof | CONCORTIS BIOSYSTEMS, CORP. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9801951-B2 | Drug-conjugates, conjugation methods, and uses thereof | CONCORTIS BIOSYSTEMS, CORP. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20160067350-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20150141646-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | Concortis Biosystems, Corp., a wholly owned subsidary of Sorrento Therapeutics, Inc, (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141646-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | Concortis Biosystems, Corp., a wholly owned subsidary of Sorrento Therapeutics, Inc, (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150105539-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. (US) | 2015-04-16 | — | — | US | disclosed |
| US-20150105539-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. (US) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180085471-A1 | DRUG-CONJUGATES, CONJUGATION METHODS, AND USES THEREOF | ABCG2, UGT2B7, UGT1A9 | SLC7A5 73/4885CXCR1 2264/4885CXCR2 1760/4885 |
| US-20160067350-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | PAICS, CES2, DNPEP | SLC7A5 448/4885CXCR1 2387/4885CXCR2 1616/4885 |
| US-20150141646-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | ABCG2, UGT2B7, UGT1A9 | SLC7A5 73/4885CXCR1 2264/4885CXCR2 1760/4885 |
| US-20210187119-A1 | Drug-Conjugates, Conjugation Methods, And Uses Thereof | PAICS, CES2, DNPEP | SLC7A5 448/4885CXCR1 2387/4885CXCR2 1616/4885 |
| US-10967071-B2 | Drug-conjugates, conjugation methods, and uses thereof | PAICS, CES2, DNPEP | SLC7A5 448/4885CXCR1 2387/4885CXCR2 1616/4885 |
| US-20150105539-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | PAICS, CES2, DNPEP | SLC7A5 448/4885CXCR1 2387/4885CXCR2 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.